Tags : Curium

RadioMedix and Curium Detectnet (copper Cu 64 dotatate injection) Receives

Shots: The approval is based on P-lll study which involves assessing Detectnet (copper Cu 64 dotatate injection) in Neuroendocrine Tumors (NETs) patients. Curium expects to launch detectnet immediately with doses available through various nuclear pharmacies The P-III results demonstrated that the clinical sensitivity and specificity provide great aid to clinicians to develop an accurate treatment […]Read More

Insights+: The US FDA New Drug Approvals in March and

The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019. In 2018, the FDA approved 59 novel products including 42 New Chemical Entity and 17 Biologics while breaking its past year’s records of approval. However, there is a […]Read More